B+
Bull case
20%
Probability
Target price
$8.00
+159.7% vs current
NTRB
NutribandBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$3.10
+0.6% vs current
B-
Bear case
30%
Probability
Target price
$1.40
-54.5% vs current
AI sentiment snapshot
Latest data as of 2026-06-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+63.1
Score
AI commentary
Low-coverage, high-idiosyncrasy biotech setup. I could not retrieve a June 1, 2026 earnings release or transcript from the primary-source packet, so the post-print surprise/revision layer remains unavailable; the report therefore leans on the latest 10-K and 8-K and stays a cautious monitoring view with downside bias despite long-dated AVERSA optionality.
RankAlpha Sentiment Codex - 2026-06-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31eventFDA/trademark review of the AVERSA brand name is an incremental regulatory stepHigh impact
The March 30, 2026 press release filed with the SEC says Nutriband selected a commercial worldwide brand name for its lead abuse-deterrent fentanyl patch and will submit the proposed name and labeling to the FDA and other regulators for review and approval; this is a small but real de-risking step for the program [#8-K-2026-04-07].
2026-12-31catalystRunway and dilution risk stay elevated until financing or development progress improvesHigh impact
The 2026 10-K shows FY2026 net loss of $8.23 million, cash used in operations of $5.13 million, and continued reliance on securities issuance and debt to fund operations; management says it expects sufficient funds for one year, but that still leaves the equity exposed to execution and financing risk [#10-K-2026-04-29].
2027-04-29catalystAVERSA Fentanyl remains the core long-horizon value driverHigh impact
The 2026 10-K says AVERSA Fentanyl is Nutriband's lead product under development, requires FDA approval, and will need substantial capital for research and development; management also says the program needs roughly $13 million for R&D, clinical manufacturing, and clinical trials, with total cost potentially higher [#10-K-2026-04-29].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-04 • Updated nightlySource: Internal modelMethodology